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Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive
and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores
represent the most widely used prognostic models, but many changes have occurred in
therapeutic protocols since their development. Moreover, many PCNSL patients cannot
be classified using the IELSG score. We thus aimed to create a novel, effective and
feasible prognostic model for PCNSL.
Methods: We included 248 PCNSL patients diagnosed with PCNSL. Our primary
endpoint was the overall survival (OS) and we used the receiver operating characteristic
(ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate
dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived
neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by
univariate and multivariate analyses. 124 out of 248 patients were randomly selected as
the internal validation cohort.
Results: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group
performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of
Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and
LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the
MSKCC score and LLR were confirmed as independent prognostic parameters forAugust 2021 | Volume 11 | Article 6961471
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Frontiers in Oncology | www.frontiersin.orgpoorer OS. OS, however, was not significantly different between low- and intermediate-
risk groups according to the MSKCC score, while LLR proved to be prognostically
relevant and was thus used to develop a novel, effective three-tier PCNSL scoring
system. Of 124 patients, 84 patients with survival data and LLR data were successfully
validated by newly established PCNSL LLR scoring system.
Conclusions: In the present study, we demonstrate that a high LLR represents an
independent unfavorable prognostic parameter in PCNSL patients which can be
integrated into an effective prognostic model.Keywords: primary central nervous system lymphoma, lactate dehydrogenase-to-lymphocyte ratio, prognostic
parameter, Memorial Sloan Kettering Cancer Center (MSKCC) score, neutrophil-to-lymphocyte ratioINTRODUCTION
Primary central nervous system lymphoma (PCNSL) is defined
as a pathologically confirmed primary lymphoma of the central
nervous system, arising within the brain, leptomeninges, spinal
cord and eyes, without systemic involvement; it represents a
highly aggressive and rare extranodal non-Hodgkin lymphoma
(NHL) with a poor prognosis. Around 90%–95% PCNSLs are
histologically classified as diffuse large B-cell lymphomas
(DLBCL) (1). Although high-dose systemic methotrexate (HD-
MTX)-based chemotherapy and whole brain radiotherapy
(WBRT) have improved the outcomes of this disease in the
last decade, its prognosis is still unsatisfactory (2). Present
median overall survival is 36.9–46 months, with a five-year
survival rate ranging from 22.3% to 32% (3–5).
Two scoring systems are commonly used to predict the
outcome of PCNSL patients: the International Extranodal
Lymphoma Study Group (IELSG) score (6) and the Memorial
Sloan Kettering Cancer Center (MSKCC) score (7). The first one
was validated in 378 PCNSL patients treated at 23 cancer centers
from five countries between 1980 and 1999. However, only 105
patients had complete data and were included in the model and
the median follow-up was 24 months only. In this study, the
IELSG found that an age >60 years, Eastern Cooperative
Oncology Group performance status (ECOG PS) >1, high level
of lactate dehydrogenase (LDH), elevated cerebrospinal fluid
protein concentration and involvement of deep regions of the
brain were significantly associated with a worse outcome. The 2-
year overall survival (OS) was 80%, 48% and 15% for patients
with 0 to 1, 2 to 3, and 4 to 5 unfavorable parameters, respectively
(6). The MSKCC score was developed within a study including
338 PCNSL patients recruited during 1983 to 2003. Age and
Karnofsky performance score (KPS) were the only two variables
included in the prognostic model, and they were used to stratify
participants into low-, intermediate-, and high-risk groups
(characterized by: age <50 irrespective of KPS, age ≥50 and
KPS ≥70, age ≥50 and KPS <70), which correlated with median
OS of 8.5, 3.2 and 1.1 years, respectively (7). Despite the clinical
usefulness of the MSKCC and IELSG prognostic models, they
should be further improved and updated considering the
progress in PCNSL treatments (e.g. rituximab availability) (6).
Moreover, a major limitation of the MSKCC prognostic model is2
an intrinsic selection bias for being a single institution study (7).
Gene mutation status and/or gene expression profiling combined
with or without the prognostic models (8) were also investigated
to predict the clinical outcomes of PCNSL. However, the use of
molecular markers is always associated with high costs,
laboratory efforts, and time-consuming procedures, which are
not routinely available in many clinical units and diagnostic
laboratories (9). Therefore, there is a growing need for cost-
effective and easily applicable prognostic markers that might help
to improve the prognostic accuracy of existing models (9).
Recent data showed that inflammation actively participates
in tumor progression, shaping the microenvironment, and
promoting cancer cell proliferation, survival and migration
(10). A series of parameters related to systemic inflammation
have been identified as prognostic factors in lymphomas,
including the lymphocyte count (11), levels of C-reactive
protein, erythrocyte sedimentation rate (ESR), neutrophil-to-
lymphocyte ratio (NLR) (12), derived neutrophil-to-
lymphocyte ratio (dNLR) (13), and lymphocyte-to-monocyte
ratio (LMR) (14). Peripheral blood count and biochemical
markers, which are simple and widely available tests, may be a
surrogate of the inflammatory and immune alterations caused by
lymphomas. However, in a recently published study, analysis
of inflammation markers alone has not proven capable of
predicting the clinical therapeutic outcomes (15). Thus, tumor
burden-associated markers, e.g. lactate dehydrogenase, and
inflammation markers such as lymphocyte counts have
been combined in the present study to develop a novel
prognostic model.
In fact, lactate dehydrogenase-to-lymphocyte ratio (LLR) is
an established prognostic parameter in extranodal natural killer/
T cell lymphoma (ENKTL) (16), metastatic renal cell carcinoma
(mRCC) (17) and DLBCL patients (18). Moreover, Dai et al.
developed a novel prognostic model based on Ann Arbor stage,
b2-microglobin to lymphocytes ratio (bLR) and LLR which
resulted an independent prognostic parameter in early stage
ENKTL patients (16). Tao et al. revealed that patients with a
LLR ≥ 150 had shorter median progression free survival (PFS)
and OS (PFS 9 months vs 18 months; OS 21 months vs 46
months) in mRCC patients treated with tyrosine kinase
inhibitors (17). In DLBCL patients, a high LLR was associated
with poor 5-year PFS and OS (PFS 45% vs 78%; OS 56% vs 86%)August 2021 | Volume 11 | Article 696147
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patients has never been explored, and thus we set out to evaluate
the hypothesis that LLR could be exploited to create a novel,
effective and feasible prognostic model for PCNSL.METHODS
Patients
We retrospectively collected data from 6 centers in 4 countries,
the Affiliated Cancer Hospital & Institute of Guangzhou
Medical University in China, ZhuJiang Hospital of Southern
Medical University in China, the First Affiliated Hospital of Jinan
University in China, Medical University of Graz in Austria,
Samsung Medical Center in Korea, and University of Turin in
Italy. We included 248 immunocompetent patients with PCNSL
diagnosed between November 2004 and December 2019. All
clinico-pathological parameters such as the histologically
confirmed diagnosis of PCNSL (DLBCL histotype), gender,
age, cell of origin categories (GCB and ABC subtype according
to the Hans algorithm), survival data, and laboratory results
were retrieved from medical records in their respective hospitals
and reviewed. All the patients included in this study fulfilled
the following criteria: (1) disease localized exclusively in the
brain, leptomeninges, spinal cord and eyes without systemic
involvement; (2) seronegative for human immunodeficiency
virus; (3) none history of immunosuppression or organ
transplantation; (4) none other malignancies diagnosed during
the observation period; (5) none previous anti-cancer treatment;
(6) adequate clinical, laboratory, and follow-up data available. All
procedures involving human participants were performed in
accordance with the ethical standards of the institutional and/
or national research committees and according to the 1964
Helsinki declaration and its later amendments or comparable
ethical standards. Considered the retrospective nature of
the study and that patients’ data had been de-identified in the
dataset, our institutional ethics review board approved the study
and waived the need for informed consent.Pre-Treatment Systematic Inflammation-
Based Prognostic Parameters
Pre-treatment laboratory parameters, including the neutrophil
count, derived neutrophil count, lymphocyte count, and serum
levels of LDH, were obtained before treatment initiation. These
data were calculated the median and interquartile range. NLR
was calculated as the absolute neutrophil count divided by the
absolute lymphocyte count, dNLR was determined as neutrophil
count divided by the result of leukocyte count minus neutrophil
count, LLR was determined as the serum level of LDH divided by
the absolute lymphocyte count.Internal Validation
124 out of 248 patients with PCNSL were randomly selected as
the internal validation cohort. The established PCNSL model was
examined in the validation cohort.Frontiers in Oncology | www.frontiersin.org 3Clinical Outcomes and Statistical Analysis
We evaluated the treatment responses as CR (complete
response), PR (partial response), SD (stable disease), and PD
(progressive disease) according to The International Working
Group Recommendations for Response Criteria of non-
Hodgkin’s lymphoma (19). Dates of death were obtained from
clinical records, official civil registries or by telephone calls to
patients’ relatives. OS was calculated in months and defined as
the time from the date offirst diagnosis to either the date of death
from any cause or the last follow-up date. Receiver-operating-
characteristics (ROC) analysis was adopted to define the optimal
cut-off value for LLR, NLR, and dNLR. Survival curves were
analyzed by the log rank test and Kaplan–Meier method. The
prognostic capability (in terms of OS) of the included variables
was evaluated by univariate Cox analysis. Significant variables
(P-value < 0.05) were included into the multivariate analysis
using the forward conditional Cox regression model. All the
statistical analyses were performed using the SPSS 16.0 software
(IBM, Armonk, New York, US) and P values (two-tailed) < 0.05
were considered to be statistically significant.RESULTS
Patient Characteristics
We included 248 patients with confirmed PCNSL, diagnosed
in 6 cancer centers. The percentage of patients participating in
each institution is shown in Figure 1. Patients’ median age at
the time of diagnosis was 59 years (range: 21–86), and 56.0%
were males. An ECOG PS of 0–1 was seen in 52.8% of the
subjects (131/248). According to the MSKCC scoring system,
most patients (58.9%, 146/248) were classified as intermediate
risk, 54 patients as low risk (21.8%) and 48 patients as high
risk (19.3%). Data regarding the cell of origin were available
for 153 patients, 117 of which had non germinal center B-cell
subtype lymphomas. Systemic B symptoms were observed in a
small fraction of the patients (6/131), while elevated LDH
levels were observed in 117 cases (47.2%). Of all 248 patients,
196 patients had EBV status data, but only 3 patients were
EBV tissue-positive cases. Baseline characteristics are shown
in Table 1.
Treatment Modalities and Response
Therapeutic data of 211 patients were available. Radiotherapy
(RT) alone was performed in 9 patients (3.6%), a combination of
RT and chemotherapy (CMT) was performed in 33 patients
(13.3%), and CMT alone was performed in 169 patients (68.1%).
Methotrexate (MTX) was the most commonly used drug (n =
173), followed by alkylating agents (n = 124, including
procarbazine, thiotepa, cyclophosphamide and temozolomide),
and cytarabine (n = 35). Chemotherapy regimens were generally
divided into HD-MTX-based regimens (n = 173) and non-HD-
MTX regimens (n = 29). Non-HD-MTX regimens included
cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) or CHOP-like regimens, prednisolone alone or
alkylating agents-based regimens. In addition, 49 (23.2%)August 2021 | Volume 11 | Article 696147
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autologous hematopoietic stem cell transplantation during
treatment. After the initial treatment, 92 (43.6%) achieved CR,
62 (28.9%) achieved PR, 7 (3.3%) experienced SD, 29 (13.7%)
had PD and in 22 (10.4%) response data were unavailable.Determination of Cut-Off Values
In this study, we used OS as the endpoint of interest and ROC
analysis was performed to calculate the optimal cut-off value for
LLR, NLR, and dNLR. The area under the ROC curve for LLR,
NLR, and dNLR were 0.616, 0.562, and 0.548, respectively
(Figure 2), and the optimal cut-off values corresponding to the
maximum joint sensitivity and specificity were 166.8, 4.74, and
3.29, respectively (Table 2).Prognostic Parameters
Using univariate analysis and Cox regression model, we assessed
the impact of LLR and of clinical characteristics on the OS.
Univariate analysis identified several potential prognostic factors
for poor OS: Age > 60 (hazard ratio [HR] 1.735, P = 0.007),
ECOG PS > 1 (HR 1.888, P = 0.001), treatment with radiotherapy
alone (HR 4.807, P = 0.010), high-risk group of MSKCC score
(HR 2.687, P = 0.004), NLR > 4.74 (HR 1.634, P = 0.023), dNLR >
3.29 (HR 1.568, P = 0.039), and LLR > 166.8 (HR 1.710, P =
0.016) (Table 3). In multivariate analysis, both LLR > 166.8 and
the MSKCC scores were independent prognostic parameters for
OS (P = 0.015 and P = 0.004, respectively) (Table 4). Conversely,
age, ECOG PS, treatment, NLR, and dNLR were not significant.Frontiers in Oncology | www.frontiersin.org 4Survival Outcomes
Of all 248 patients, 193 patients had sufficient data to evaluate the
prognostic significance of MSKCC, while 166 patients had both
LLR data and MSKCC data. Most of the patients (n=103) died
during the follow-up and the median OS was 33 months (95% CI
20.2–45.8). The 3-year and 5-year OS rates of the 193 patients
were 48.4% and 30.2%, respectively. Patients with LLR ≤ 166.8
had a median OS of 50 months (n = 89), while those with LLR >
166.8 had a median OS of 32 months (n = 77) (P = 0.016)
(Figure 3A). Although the OS rates of patients in the low-,
intermediate-, and high-risk groups of the MSKCC scoring
system were significantly different overall, with 5-year OS rates
of 37.5% (n = 44), 33.7% (n = 111), and 14.1% (n = 38) (P =
0.004) (Figure 3B) (Table 5), there was no statistical difference
between the low-risk and intermediate-risk groups (P = 0.184,
data not shown). Similarity, the median OS of patients in the
low-, intermediate-, and high-risk groups of the MSKCC scoring
system were significantly different overall, with 5-year OS rates of
44, 39, and 17 months, respectively (P = 0.004) (Table 5), but
there was no statistical difference between the low-risk and
intermediate-risk groups (P = 0.184, data not shown).
LLR Further Stratified Patients With Low
and Intermediate MSKCC Risk
We further investigated whether LLR could stratify this latter
group including patients with low and intermediate MSKCC
scores. Our results showed that patients with LLR ≤ 166.8 had a
significantly better OS than those with LLR > 166.8 within this
group (P = 0.007) (Figure 3C) (Table 5). Based on this result, a
novel three-tier PCNSL LLR prognostic scoring system wasFIGURE 1 | The percentage of patients participating in each institution.August 2021 | Volume 11 | Article 696147
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risk group were retained (i.e. age ≥50 and KPS <70), while the
former low and intermediate risk patients defined according to
the MSKCC criteria (i.e. age <50 or age ≥50 and KPS ≥70) were
stratified by LLR. Accordingly, the resulting risk groups were so
defined: low-risk (age <50 or KPS ≥70, and LLR ≤ 166.8),
intermediate-risk (age <50 or KPS ≥70, and LLR > 166.8) and
high-risk (age ≥50 and KPS <70). Outcomes of patients within
the low-, intermediate-, and high-risk groups of the novel
PCNSL LLR score resulted significantly different, with 5-year
OS rates of 56.1% (n = 70), 26.6% (n = 63), and 14.1% (n = 38),
respectively (P < 0.001) (Figure 3D) (Table 6). Similarity, the
median OS of patients in the low-, intermediate-, and high-risk
groups of the novel PCNSL LLR scoring system were
significantly different overall, with 5-year OS rates of 74, 33,
and 17 months, respectively (P < 0.001) (Table 6).
Validation of the Novel PCNSL LLR
Scoring System
We randomly selected 124 PCNSL patients out of 248 for the
validation purpose. Of the 124 patients, 84 patients had survival
data and LLR data simultaneously. The prognostic score that we
developed in the discovery stagewas tested in the validation cohort.Frontiers in Oncology | www.frontiersin.org 5Figure 4A shows that the OS rates of patients in the low-,
intermediate-, and high-risk groups of the MSKCC scoring
system were significantly different overall, with 5-year OS rates of
33.3% (n = 16) and 40.9% (n = 49), and 11.6% (n = 19), respectively
(P = 0.008). However, MSKCC score could not discriminate
patients within low-, and intermediate- groups in the validation
cohort (P = 0.243) (Figure 4A) (Table 7). The newly established
score can clearly distinguishpatientswithin the low-, intermediate-,
and high-risk groups in the validation cohort, with 5-year OS rates
of 61.9% (n = 33), 30.2% (n = 32), and 11.6% (n = 19), respectively
(P = 0.005) (Figure 4B) (Table 7).DISCUSSION
In our present study, univariate analysis showed that age, ECOG
PS, treatment, MSKCC score, NLR, dNLR, and LLR were
significantly associated with the OS of PCNSL patients. However,
only MSKCC score and LLR were confirmed as predictors of OS by
multivariate analysis. When LLR was introduced, patients within
the low and intermediate risk groups, defined according to the
MSKCC scoring system, were clearly separated into two groups
with significantly different OS. Thus, the novel PCNSL LLR scoring
system showed powerful prognostic value in PCNSL patients.
Specifically, the performed ROC analysis allowed to determine
an optimal LLR cut-off value of 166.8 as a relatively sensitive and
specific prognostic marker for PCNSL.
Tumor cells prefer glycolysis to oxidative phosphorylation,
even in presence of oxygen. This phenomenon, known as the
Warburg’s effect, seems to be crucial for tumor development.
Lactate dehydrogenase A (LDH-A) is a key enzyme in thisFIGURE 2 | Receiver operating characteristic (ROC) curve of NLR, dNLR and
LLR. The area under the ROC curve (AUC) of LLR was 0.616, which was
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HD-MTX, high-dose methotrexate; MSKCC, Memorial Sloan Kettering Cancer Center.August 2021 | Volume 11 | Article 696147
Gao et al. A Prognostic Marker for PCNSLprocess, which catalyzes pyruvate to produce lactic acid (20). In
many cancers, the level of serum lactate dehydrogenase is an
indirect marker of tumor hypoxia, neo-vascularization,
metastasis development and poor prognosis (21). In addition,Frontiers in Oncology | www.frontiersin.org 6high expression of LDH is significantly related to the lack of
lymphocyte infiltration at the invasive tumor border, to impaired
host immune response, and to enhanced angiogenesis, resulting
in poorer patient prognosis (22). Indeed, there is evidence thatTABLE 3 | Univariate analysis of variables associated with overall survival.
Parameter (median, IQR) HR (95%CI) P value
Age ≤60 (52, 8) 0.007
>60 (68, 10) 1.735 (1.163,2.588)
Gender Male – 0.705
Female – 0.927 (0.624,1.375)
ECOG PS ≤1 – 0.001
>1 – 1.888 (1.278,2.789)
B symptom Yes – 0.480
No – 0.599 (0.145,2.483)
Cell of origin GCB – 0.088
Non GCB – 0.555 (0.282,1.091)
EBV Negative – 0.481
Positive – 2.047 (0.280,14.989)
Treatment Chemotherapy – – – 0.010
Radiotherapy – 4.807 (1.724,13.407)
CMT+RT – 1.250 (0.676,2.311)
MSKCC Low – – – 0.004
Intermediate – 1.461 (0.838,2.545)
High – 2.687 (1.446,4.991)
LDH ≤250 U/L (179, 53) 0.255
>250 U/L (384, 157) 1.289 (0.823,1.997)
NLR ≤4.74 (2.19, 1.46) 0.023
>4.74 (7.28, 5.56) 1.634 (1.069,2.498)
dNLR ≤3.29 (1.66, 0.96) 0.039
>3.29 (5.06, 3.27) 1.568 (1.023,2.405)




Neutrophil ≤2.0×109/L (1.76, 0.26) 0.644
>2.0×109/L (5.05, 3.76) 1.593 (0.222,11.448)
Lymphocyte ≤1.5×109/L (1.05, 0.39) 0.110
>1.5×109/L (2.10, 0.91) 0.712 (0.469,1.080)August 2021 | Volume 11 | ArticleIQR, interquartile range; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; EBV, Epstein-Barr
virus; CMT, chemotherapy; RT, radiotherapy; MSKCC, Memorial Sloan Kettering Cancer Center; LDH, lactate dehydrogenase; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived
neutrophil-to lymphocyte ratio; LLR, lactate dehydrogenase-to-lymphocyte ratio.TABLE 4 | Multivariate analysis of variables associated with overall survival.




MSKCC Low – 0.004
Intermediate 1.133 (0.613,2.096)
High 2.937 (1.459,5.908)HR, hazard ratio; CI, confidence interval; LLR, lactate dehydrogenase-to-lymphocyte ratio; MSKCC, Memorial Sloan Kettering Cancer Center.TABLE 2 | Determination of the optimal cut-off values.
Marker Cut-off values AUC 95% CI P value
NLR 4.74 0.562 0.478—0.646 0.15
dNLR 3.29 0.548 0.463—0.632 0.27
LLR 166.80 0.616 0.530—0.701 0.01NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; LLR, lactate dehydrogenase-to-lymphocyte ratio; AUC, area under receiver operating curve; CI,
confidence interval.696147
Gao et al. A Prognostic Marker for PCNSLdirect targeting of LDH is a potential therapeutic approach in
cancer (23). Elevated serum LDH has been recognized as a poor
prognostic indicator for hematological malignancies and solid
tumors as well; moreover LDH has the highest prognostic impact
among the International Prognostic Index (IPI) risk factors (24).
Serum LDH is considered as an excellent surrogate marker of
tumor burden in DLBCL patients. In addition, it is inexpensive
and can be easily assessed during the routine clinical practice (14).
Host immune system, systemic inflammation and tumor
microenvironment all contribute to malignancy developmentFrontiers in Oncology | www.frontiersin.org 7and progression (25). Recently, a low absolute lymphocyte count
(ALC) has been proposed as a novel, independent prognostic
parameter of poor survival in patients with NHL, such as DLBCL,
ENKTL and follicular lymphoma (FL). One study specifically
assessed ALC at diagnosis as a prognostic marker in PCNSL:
Ji et al. analyzed 81 PCNSL patients who received high-dose
methotrexate-based therapy and developed a new prognostic
model including age >50 years, ECOG PS >1 and presence of
lymphopenia. They successfully classified patients into low-,
intermediate-, and high-risk groups observing 5-year OS rates ofA B
C D
FIGURE 3 | Kaplan–Meier curves for OS according to the LLR (P = 0.016) (A) and MSKCC score (P = 0.004) (B). Overall survival Kaplan–Meier curves according to
the LLR of low-intermediate MSKCC risk patients (P = 0.007) (C). Kaplan–Meier curves according to the novel PCNSL LLR scoring system (P < 0.001) (D).TABLE 5 | Survival outcomes of the assessable patients according to the different risk groups.
Models and risk groups Patient, n Median OS 5-Year OS rates HR (95%CI) P value
MSKCC score 0.004
Low-risk 44 (23%) 44 37.5% –
Intermediate-risk 111 (57%) 39 33.7% 1.461 (0.838,2.545)
High-risk 38 (20%) 17 14.1% 2.687 (1.446,4.991)
LLR 0.016
Low (≤166.8) 89 (54%) 50 43.4% –
High (>166.8) 77 (46%) 32 25.4% 1.710 (1.105,2.646)
Low-intermediate MSKCC risk 0.007
LLR ≤ 166.8 70 (53%) 74 56.1% –
LLR > 166.8 63 (47%) 33 26.6% 2.082 (1.221,3.552)August 2021 | Volume 11 | ArticleMSKCC, Memorial Sloan Kettering Cancer Center; OS, overall survival; LLR, lactate dehydrogenase-to-lymphocyte ratio; the median overall survival time is calculated in months.696147
Gao et al. A Prognostic Marker for PCNSL74.3%, 21.7% and 12.5%, respectively (11). Decreased peripheral
ALC may represent a surrogate biomarker of compromised anti-
tumor host immunity in PCNSL patients. Lymphopenia may
contribute to insufficient production of chemokines with anti-
neoplastic activity such as interferon-g, tumor necrosis factor, or
interleukin-1. In addition, perivascular lymphocyte infiltration
may be impaired in patients with lymphopenia and it can also
increase the risk of treatment-associated complications which may
affect patient survival (11). Based on these previous studies, we
hypothesized that the ratio between a tumor burden marker
(LDH) and an inflammation marker (lymphocyte count) (i.e.
LLR), may represent an ideal prediction tool for estimating the
outcome of PCNSL patients. Using a LLR cut-off of 166.8, our
survival analysis stratified patients into two groups with median
OS of 50 months (LLR ≤ 166.8) and 32 months (LLR > 166.8),
respectively. To assess the importance of the specific LLR cut-off
value, we also re-evaluated in our series a threshold which had
been previously suggested for Extranodal NK/T Cell Lymphoma,
Nasal Type (16), but we did not detect a survival difference
between patients with low (≤128.44) and high (>128.44) LLR
values (P = 0.143, data not shown). This observation highlights the
importance of identifying and testing specific cut-off values for
each tumor type.Frontiers in Oncology | www.frontiersin.org 8Todate, age andECOGPS are the only two universally accepted
prognostic parameters for PCNSL, indeed age >60 years and
performance status >1 resulted clearly associated with a worse OS
(26). A nationwide survey, which is the largest-scale PCNSL study
to date, conducted on 466 patients treated at 62 Japanese
institutions confirmed the above results (27). Recent studies have
suggested that NLR is an independent prognostic parameter in
patients with lymphomas, such as FL and DLBCL. In a study
focused on NLR in PCNSL, Jung et al. demonstrated that NLR
might play a potentially prognostic role in PCNSL by analyzing a
cohort of 62 histologically confirmed cases. Nevertheless, no
significant association was observed by multivariate analysis (28).
Our study also identified a potential prognostic value of NLR in
PCNSL, although the result was thennot confirmed bymultivariate
analysis. Elevated dNLR level is an independent poor prognostic
parameter in patients with multiple myeloma who are not suitable
for transplantation (29). InDLBCL, an independent and significant
correlationbetweendNLRandpoorOSandDFSwas reported (13).
By univariate analysis, we found that high dNLR was associated
with poor OS, but the real significance of this parameter has to be
ascertained since it was also not confirmed bymultivariate analysis.
Nevertheless, this is the first time that the prognostic significance of
pre-treatment dNLR is suggested in PCNSL.TABLE 6 | The novel PCNSL LLR scoring system.
Model Patient, n Median OS 5-Year OS rates HR (95%CI) P value
PCNSL LLR score <0.001
Low-risk 70 (41%) 74 56.1% –
Intermediate-risk 63 (37%) 33 26.6% 2.091 (1.226,3.565)
High-risk 38 (22%) 17 14.1% 3.668 (2.072,6.493)August 2021 | Volume 11 | ArticleOS, overall survival; the median overall survival time is calculated in months; low-risk (age <50 or KPS ≥70, and LLR ≤ 166.8), intermediate-risk (age <50 or KPS ≥70, and LLR > 166.8) and
high-risk (age ≥50 and KPS <70).A B
FIGURE 4 | Kaplan–Meier curve for OS according to the MSKCC scoring system (A) and PCNSL LLR scoring system (B) in the validation cohort. The OS rates of
patients in the low-, intermediate-, and high-risk groups of the MSKCC scoring system were significantly different overall, with 5-year OS rates of 33.3% (n = 16) and
40.9% (n = 49), and 11.6% (n = 19), respectively (P = 0.008). MSKCC scoring system could not discriminate patients within low-, and intermediate- groups in the
validation cohort (P = 0.243) (A). PCNSL LLR scoring system can clearly distinguish patients within the low-, intermediate-, and high-risk groups in the validation
cohort (P = 0.005) (B).696147
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efficacy of these scores, also tailoring them to patients treated
with the current HD-MTX-based regimens (30). IPI, an
internationally recognized prognostic scoring system for non-
Hodgkin’s lymphomas, is commonly used to evaluate the
prognosis of DLBCL and could represent a possibly alternative.
However, the definition of number/sites of involvement and stage
is controversial for PCNSL and thus it is rarely used in this setting.
The MSKCC and the IELSG scores represent the most widely used
prognostic models for PCNSL. In fact, the MSKCC score is a
simplified version of the IELSG score, which takes into
consideration more parameters beyond age and KPS.
Unfortunately, many of these variables were not uniformly
collected or reported in routine clinical practice, especially in
older time periods. In addition, CSF examination is often
avoided in PCNSL patients because of the potential risk of
complications due to the increased intracranial pressure, thus
CSF protein levels are not always available (31). For instance,
one research enrolled 79 patients with intracranial PCNSL and
successfully validated the MSKCC score, but failed to confirm the
prognostic efficacy of the IELSG score, and in 9 out of the 79
patients (11%) the IELSG score could not be calculated due to the
lack of CSF protein levels (31). Consequently, many PCNSL
patients cannot be classified using the IELSG score during the
daily practice while using the MSKCC score is always possible.
Some researchers also propose the Nottingham and Barcelona
scoring system (NB), which is a three-factor scoring system,
consisting of age, ECOG PS, presence of multifocal lesions or
meningeal disease. It was developed in a relatively small cohort
with 77 PCNSL patients that received CHOD/BVAM or BVAM
chemotherapy regimens, so its value and application may be
limited (32). Moreover, a study evaluated the validity of the
existing scores: the IELSG, the NB, and the MSKCC in 182 newly
diagnosed PCNSL patients. The IELSG and NB models showed
poor separation for both PFS and OS, while the MSKCC score
demonstrated a significant discrimination in terms of PFS in the
training cohort. Based on these data, the IELSG, NB, and
MSKCC scores showed an insufficient prognostic capability,
although the MSKCC score performed better than the IELSG
and NB models (33). These limitations of the proposed
prognostic scoring systems highlight the importance of real-life
feasibility when proposing novel prognostic models.
Based on the reasons above, our study only considered the
MSKCC score as a control prognostic model. As expected, survivalFrontiers in Oncology | www.frontiersin.org 9curves of the low-, intermediate-, and high-risk MSKCC groups
varied significantly in our cohort, but no difference was observed
between the low-risk and intermediate-risk groups, a finding
which could be explained by the substantial changes in terms of
therapeutic regimens which occurred since the development of the
MSKCC score (11). Compared with the MSKCC score, LLR
showed a superior prognostic value and could successfully
classify patients into different risk groups: the novel PCNSL LLR
scoring system was able to define three prognostically relevant
groups of patients and in particular to further stratify the low/
intermediate MSKCC risk groups. Therefore, the PCNSL LLR
scoring system could represent a novel, objective, commonly
available, cost-effective and accurate prognostic predictor of
PCNSL outcome.
To our knowledge, the majority of the prognostic parameters
for PCNSL have been validated by single center studies, which
are inevitably subjected to an internal selection bias. Hopefully,
the multicenter nature of our study helped control these biases,
although it hampered the collection of fully comprehensive
clinical data and thus it was not possible to analyze PFS, which
is commonly used to prove the prognostic significance of a novel
marker. Moreover, since the included patients were diagnosed
within an extended period of time (2004-2019), the performed
examinations and assessments varied in the different centers and
time periods; in particular, some tests were not routinely done in
the early years, and thus the IELSG score could not calculated.
Finally, considering the low incidence of PCNSL, one major
limitation of the present study is the lack of validation in the
external cohort. This pitfall could be partially balanced by its
multicenter nature and internal validation cohort which could
support the general validity of the observed results, but this
prognostic model should be validated in an independent external
cohort and a multicenter prospective study is thus warranted in
the near future to consolidate our findings.CONCLUSION
In the present study, we demonstrated the prognostic role of LLR
in PCNSL patients. Besides, we proposed a novel PCNSL LLR-
based scoring system which was able to improve the prognostic
capability of the MSKCCmodel. The PCNSL LLR scoring system
can be easily and routinely determined without additional
expensive work-ups, thus it should be prospectively validatedTABLE 7 | Validation of the novel PCNSL LLR scoring system.
Model Patient, n Median OS 5-Year OS rates HR (95%CI) P value
MSKCC score 0.008
Low-risk 16 (19%) 44 33.3% –
Intermediate-risk 49 (58%) 48 40.9% 1.913 (0.665,5.503)
High-risk 19 (23%) 18 11.6% 4.521 (1.476,13.848)
PCNSL LLR score 0.005
Low-risk 33 (39%) 74 61.9% –
Intermediate-risk 32 (38%) 32 30.2% 1.920 (0.898,4.108)
High-risk 19 (23%) 18 11.6% 3.899 (1.712,8.882)August 2021 | Volume 11 | ArticleMSKCC, Memorial Sloan Kettering Cancer Center; OS, overall survival; the median overall survival time is calculated in months; HR, hazard ratio; CI, confidence interval; low-risk (age <50
or KPS ≥70, and LLR ≤ 166.8), intermediate-risk (age <50 or KPS ≥70, and LLR > 166.8) and high-risk (age ≥50 and KPS <70).696147
Gao et al. A Prognostic Marker for PCNSLto enable its use in the daily practice, possibly also to tailor the
therapeutic regimens of PCNSL patients.DATA AVAILABILITY STATEMENT
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